Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Avalo Therapeutics (AVTX) has 8 years of Receivables data on file, last reported at $44000.0 in Q2 2023.

• Quarterly Receivables fell 98.01% year-over-year to $44000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $44000.0 (down 98.01% YoY) and the FY2022 annual result came in at $1.9 million, down 60.01% from the prior year.
• Receivables slipped to $44000.0 in Q2 2023, from $605000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $5.6 million in Q1 2019 to a low of -$2.5 million in Q2 2019.
• A 5-year average of $2.2 million and a median of $2.2 million in 2022 frame the typical range for Receivables.
• The widest YoY moves for Receivables: up 4153.55% in 2019, down 2198.36% in 2019.
• Tracing AVTX's Receivables over 5 years: stood at $1.1 million in 2019, then plunged by 91.25% to $100000.0 in 2020, then jumped by 2222.0% to $2.3 million in 2021, then sank by 73.94% to $605000.0 in 2022, then plunged by 92.73% to $44000.0 in 2023.
• The last three Receivables figures came in at $44000.0 (Q2 2023), $605000.0 (Q4 2022), and $2.1 million (Q3 2022), per Business Quant data.